Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 45Neoplasm Metastasis 6Glioma 6Glioblastoma 6Neoplasms 5Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Ovarian Neoplasms 3Liposarcoma 3Diffuse Intrinsic Pontine Glioma 3Astrocytoma 3Recurrence 2Prostatic Neoplasms 2Meningioma 2Medulloblastoma 2Fallopian Tube Neoplasms 2Breast Neoplasms, Male 2Breast Cancer Metastatic 2Venous Thromboembolism 1Triple Negative Breast Neoplasms 1Thymus Neoplasms 1Sarcoma, Synovial 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Oligodendroglioma 1Non functioning pancreatic endocrine tumor 1Neurofibrosarcoma 1

Interventions

tucatinib 1tremelimumab 1trastuzumab biosimilar HLX02 1ribociclib 1pertuzumab 1durvalumab 1bintrafusp alfa protein, human 1Trastuzumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1PF-05280014 1Ontruzant 1Ogivri 1Immunoglobulin G 1High-Energy Shock Waves 1Fulvestrant 1Docetaxel 1Disulfides 1Carboplatin 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anatomic Stage II Breast Cancer AJCC v8 × ribociclib × Clear all
NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡